ST-Segment Elevation Myocardial Infarction in the Time of COVID-19

This study cites the experience of 6 sites during the first month of the COVID-19 pandemic in New York. All patients included had a confirmed diagnosis of coronavirus infection and also ST-segment elevation on electrocardiography.

Eighteen patients met these criteria. We are used to large randomized studies; consequently, this small registry of less than 20 people seems to fall short, but it is all we have so far.

The mean age for the studied subjects was 63 years old and most patients were male. Only a third of this group experienced chest pain along the ST-segment elevation.

Half the patients admitted with COVID-19 symptoms had ST-segment elevation in the initial electrocardiography, while all others developed it during hospitalization.

Half the group (9 patients) ended up in the cath lab; 6 patients had obstructive lesions and 5 underwent angioplasty.


Read also: Procedural Rescheduling Criteria in the Pandemic Era.


About half these patients had a “conventional” ST-segment elevation myocardial infarction; the other half experienced myocardial injury without any associated coronary disease.

Most included patients (72%) passed away at the hospital (4 patients with coronary disease and 9 with myocardial injury without coronary lesions).

In this series of patients affected by the new coronavirus and ST-segment elevation, there was a high prevalence of nonobstructive disease and a high mortality rate.


Read also: Reperfusion in the Time of COVID-19. What Has Changed?


Myocardial injuries in patients with COVID-19 may result from plaque rupture, cytokine storm, hypoxic injury, coronary spasm, microthrombi, or direct endothelial injury.

All patients had interstitial edema on magnetic resonance imaging.

10-1056-NEJMc2009020

Original Title: ST-Segment Elevation in Patients with Covid-19 — A Case Series.

Reference: Sripal Bangalore et al. The New England Journal of Medicine, article in press.   


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....